InsiderTrades.com logo
Write this ticker symbol down…
From StocksToTrade   |   Ad
A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.
Discover the #1 company leading this revolution

ACST Insider Trading

Insider Ownership Percentage: 13.51%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Acasti Pharma Insider Trading History Chart

This chart shows the insider buying and selling history at Acasti Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Acasti Pharma Share Price & Price History

Current Price: $3.01
Price Change: ▲ Price Increase of +0.01 (0.33%)
As of 10/2/2024 10:59 AM ET

This chart shows the closing price history over time for ACST up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
CRUSHED: How Biden's Replacement Will Devastate Your 401(k)!
From Golden Crest   |   Ad
Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.
>> Get Your FREE Wealth Protection Guide <<

Acasti Pharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/25/2023Vimal KavuruDirectorBuy676,371$1.85$1,251,286.351,188,076View SEC Filing Icon  
8/31/2023Donald OldsDirectorBuy381$2.05$781.05381View SEC Filing Icon  
See Full Table
Next Week Elon Could Trigger a Boom in this Sub-$3 Stock
From InvestorPlace   |   Ad
Next week, you’ll have a chance to get in on the ground floor of what could be Elon’s next big thing. You see, he’s set to reveal his new AI product that I believe will shock the world…
Click here to see the details and save your seat.

SEC Filings (Institutional Ownership Changes) for Acasti Pharma (NASDAQ:ACST)

6.08% of Acasti Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ACST by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Acasti Pharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/7/2024AIGH Capital Management LLC641,083$1.88M0.6%+28.9%6.821%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Securities LLC13,370$27K0.0%N/A0.051%Search for SEC Filing on Google Icon
11/12/2021Edmond DE Rothschild Holding S.A.12,500$25K0.0%-87.5%0.048%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC732,222$0.41M0.0%-19.9%2.811%Search for SEC Filing on Google Icon
8/16/2021Squarepoint Ops LLC94,500$53K0.0%+392.4%0.045%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC1,744,236$0.98M0.0%N/A0.837%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC146,784$82K0.0%-15.9%0.070%Search for SEC Filing on Google Icon
5/19/2021Virtu Financial LLC913,651$0.55M0.0%+32.8%0.438%Search for SEC Filing on Google Icon
5/18/2021Jane Street Group LLC100,617$60K0.0%N/A0.048%Search for SEC Filing on Google Icon
5/17/2021Edmond DE Rothschild Holding S.A.100,000$60K0.0%N/A0.048%Search for SEC Filing on Google Icon
2/24/2021Virtu Financial LLC687,985$0.22M0.0%+412.3%0.710%Search for SEC Filing on Google Icon
2/11/2021Oppenheimer & Co. Inc.224,965$73K0.0%+15.5%0.232%Search for SEC Filing on Google Icon
2/10/2021Renaissance Technologies LLC1,924,000$0.63M0.0%N/A1.986%Search for SEC Filing on Google Icon
12/11/2020Virtu Financial LLC134,296$27K0.0%-46.8%0.139%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Acasti Pharma logo
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Read More on Acasti Pharma

Today's Range

Now: $3.01
Low: $3.01
High: $3.01

50 Day Range

MA: $2.59
Low: $2.20
High: $3.12

52 Week Range

Now: $3.01
Low: $1.98
High: $3.59

Volume

274 shs

Average Volume

21,346 shs

Market Capitalization

$28.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Who are the company insiders with the largest holdings of Acasti Pharma?

Acasti Pharma's top insider shareholders include:
  1. Vimal Kavuru (Director)
  2. Donald Olds (Director)
Learn More about top insider investors at Acasti Pharma.
Potential $75B+ Market Opportunity in Aviation…
From Market JAR   |   Ad
[Investor Alert] Could this Company become The Tesla of Aviation?
Click here for all the details about Surf Air Mobility…